If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
193
results.
Updated on
06/08/2025 [06:51:00]
Results 25 to 50 of 193
Absstract of: MX2025006643A
The present invention provides a cycloalkane-based lipid compound of chemical formula 1, and a pharmaceutically acceptable salt thereof. The cycloalkane-based lipid compound is formed such that a carbonyl-based substituent is bonded to a central structure of a cycloalkane. The cycloalkane-based lipid compound according to the present invention is used as an ionizable lipid, which is one component of lipid nanoparticles for delivering nucleic acids.
Absstract of: MX2025004314A
The present invention relates to compounds of formula (I). The invention also extends to micro- or nanoparticles comprising a compound of formula (I). For instance, compounds of formula (I) can be used to produce stable lipid nanoparticles (LNPs). The LNPs have high encapsulation efficiency and can be used to deliver a therapeuticor prophylactic agent to a patient.
Absstract of: CN120399089A
本发明公开了一种单核细胞增生李斯特菌多表位融合抗原及基纳米颗粒和应用，本发明对LM抗原重要抗原蛋白基因编码蛋白的氨基酸序列进行分析，筛选出优势抗原表位按照一定的排列组合进行串联，构建并合成多表位融合抗原基因LM‑MeAg，进一步将LM多表位融合抗原LM‑MeAg基因在大肠杆菌中的表达，通过分子克隆技术构建pT‑LM‑MeAg5重组质粒。本发明通过编码柔性肽氨基酸的核苷酸将LM重要抗原LLO、ActA、InlB和MPL的优势抗原表位按照一定排列组合串联组装在一起，构建了LM多表位融合抗原基因，进一步制备了LM多表位融合抗原蛋白具有强免疫原性的LM‑MeAg5‑PLGA纳米颗粒分子，可用于研发制备高效、安全的抗LM疫苗或药物。
Absstract of: CN120398703A
本发明涉及药物递送技术领域，特别是涉及可电离脂质化合物及其应用。本发明提供一种同时含有#imgabs0#片段的可电离脂质化合物，其化学结构如式(Ⅰ)所示。本发明还提供了所述可电离脂质化合物的用途。本发明提供的包含可电离脂质化合物的mRNA‑LNP，能够整体提高LNP的生物相容性以及mRNA转染效率，尤其是应用到细胞治疗领域，可以实现将嵌合抗原受体(CAR)高效递送到T细胞、NK细胞、巨噬细胞等极难转染的细胞，具有意想不到的技术效果。
Absstract of: CN120392675A
本申请涉及中药提取物技术领域，尤其是涉及一种具有基因修复细胞修复作用的中药提取物及其制备工艺，其由黄芪甲苷、漆黄素、HA‑PLGA、FA‑PEG‑CRGDK等原料组成。通过构建核壳结构递送系统，实现活性成分时序释放，快速清除ROS并激活Nrf2通路促进DNA损伤修复。制备工艺包括内核载药体系构建、核壳结构组装、磷脂膜包覆及冷冻干燥等步骤。本申请能够提高活性成分利用率，增强稳定性与靶向性，适用于因氧化应激导致的DNA损伤修复，解决了传统中药复方制剂协同作用差的问题，降低了生产成本，具有广泛的应用前景。
Absstract of: CN120392698A
本发明公开了一种PLGA包裹姜黄素纳米制剂、制备方法及应用，将PLGA和姜黄素分别溶解于DMSO溶液，分别形成质量浓度为20mg/mL的基础溶液；在水浴超声的状态下，在姜黄素的基础溶液中加入PLGA的基础溶液，得到混合溶液A，其中姜黄素与PLGA的质量比为1:2.5～1:10；将混合溶液A在水浴超声状态下缓慢加入浓度为2％的PVA水溶液中，得到混合溶液B；将混合溶液B置于水溶液中透析过夜，得到PLGA包裹姜黄素纳米制剂。本发明有效克服了姜黄素水溶性差和口服生物利用度低的问题，对仔猪抗PEDV感染具有良好的保护作用，有效的降低仔猪腹泻率，能够广泛用于畜禽养殖场所PEDV的防控。
Absstract of: CN120392695A
本申请涉及生物医药技术领域，尤其是涉及一种用于肿瘤治疗的仿生脂质体载药系统及其制备方法和应用，该仿生脂质体载药系统具有高的包封率和良好的稳定性，并能有效抵抗免疫细胞的吞噬和清除，将药物高效地送达乳腺癌等肿瘤靶点，显著提高纳米药物的利用度。仿生脂质体载药系统包括脂质体药物和包裹所述脂质体药物的杂交细胞膜，其中所述脂质体药物包括BAY‑876和花菁染料，所述杂交细胞膜由巨噬细胞膜和肿瘤细胞融合形成。
Absstract of: CN120393000A
本申请属于药物靶向载体技术领域，更具体地，涉及一种靶向改造淋巴结增强抗肿瘤治疗疗效的树突状细胞来源载药囊泡及制备方法。包括过表达肿瘤抗原的树突状细胞产生的胞外囊泡，以及该胞外囊泡包裹的小分子药物；上述小分子药物为活化态成纤维细胞网状细胞去激活剂。该树突状细胞来源载药囊泡具有显著的淋巴结归巢能力，能够直接激活CD8+T细胞以及调控淋巴结成纤维细胞网状细胞的功能，协同优化CD8+T细胞的存活环境，促进CD8+T细胞的招募、活化和增殖，并驱动CD8+T细胞分化为干性记忆细胞亚群，通过多维度协同增效，增强抗原递呈，促进T细胞活化与记忆形成，改善淋巴结微环境和肿瘤微环境，有效抑制肿瘤生长。
Absstract of: CN120392701A
本发明公开了一种基于中空介孔氮化碳的纳米探针及其制备方法和应用，属于医药技术领域。制备方法包括如下步骤：S1、利用硬模板法合成中空介孔氮化碳HCNS；S2、HCNS与KSCN进行水热反应合成改性中空介孔氮化碳HCNxS；S3、将HCNxS分散于DOX/PBS溶液中，DOX充分负载于HCNxS上得到DOX@HCNxS，利用活化的HA封闭HCNxS的孔道，得到DOX@HCNxS‑HA。DOX@HCNxS‑HA的中空结构赋予了其DOX 19.05％的负载率，表面两性特性与HA修饰实现CD44受体介导的肿瘤靶向递送，并在酸性微环境中触发pH响应药物释放；DOX@HCNxS‑HA可通过ROS介导来破坏溶酶体膜与质子海绵效应，显著降低溶酶体共定位率(皮尔逊相关系数从0.73降至0.18)，促进DOX在肿瘤细胞内富集，使MDA‑MB‑231细胞存活率降至13.8％，具备对乳腺癌细胞的杀伤作用。
Absstract of: WO2025157978A1
The present invention relates to ionizable lipids for use in lipid nanoparticles, lipid nanoparticle formulations comprising these ionizable lipids, alone or in combination with other lipids and/or polymers. The lipid nanoparticles formulations may be formulated with nucleic acids for their delivery to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration.
Absstract of: WO2025156577A1
A preparation method for and use of a scopoletin-functionalized magnetic nanoprobe. The preparation method comprises steps such as preparation of amino-terminal modified nanoparticles Fe3O4@SiO2-NH2, preparation of a photoaffinity linker-scopoletin conjugate, preparation of the scopoletin-functionalized magnetic nanoprobe, etc. The method features simple and rapid operation, and eliminates the need for prior clarification of the structure-activity relationship of the active compounds, without compromising all-round contact between the active compounds and target proteins. The prepared scopoletin-functionalized magnetic nanoprobe is used for target fishing in cellular and animal models of rheumatoid arthritis. After the captured target proteins are isolated and subjected to mass spectrometry identification, a western blot experiment successfully verifies vimentin as the target protein of scopoletin on HFLS-RA cell membranes, thereby providing a novel therapeutic target for rheumatoid arthritis.
Absstract of: WO2025156581A1
Provided are a bionic drug-loaded nanoparticle with expressed CXCR4, a method for preparing same, and use thereof. The method comprises: mixing a lactic acid-glycolic acid copolymer and an immunosuppressant in a certain ratio, and preparing the mixture into a drug-loaded nanoparticle using a microfluidic technology; preparing an MSC cell stably expressing membrane protein CXCR4 and lysing same to extract the cell membrane, so as to give an engineered stem cell membrane; and fusing the engineered stem cell membrane with the drug-loaded nanoparticle to give a bionic drug-loaded nanoparticle with expressed CXCR4. The bionic drug-loaded nanoparticle with expressed CXCR4 is a bionic cell membrane drug-loaded nanoparticle with chemotaxis functionality. By means of genetic engineering, the engineered stem cell membrane is modified to encapsulate a therapeutic agent, and directionally migrates to the lesions in the body and targets specific cells, thereby improving the drug distribution in vivo and reducing adverse effects of immunosuppressants.
Absstract of: US2025241866A1
Substances in the form of flexible disks to modulate mechanotransduction mediated by integrins were designed. Two main ideas for the design are as follows. First, the radius of the disk can be prescribed to specify the radius of mechanically perturbed integrin clusters. By using disks with a greater radius value, the vinculin binding site activation vs. force relation can be amplified and shifted to the positive direction along the input axis. Second, by recruiting a certain integrin whose affinity values to talins are higher than those of other integrins into the cluster, the radial distance from the center of clusters to the point where the membrane tightly adheres to the cytoskeleton can be decreased. This results in the increase of the maximum slope of the vinculin binding site activation vs. force relation. The design can be used in the development of drugs for diseases associated with dysfunctions in integrin-mediated systems.
Absstract of: US2025241865A1
Nanoparticles useful for drug delivery are described. In one aspect, the nanoparticles contain poly(amine-co-ester)s or poly(amine-co-amide)s (PACE) modified with poly(ethylene glycol) (PACE-PEG), and can be optionally blended with a second PACE polymer optionally containing endgroup modifications. In another aspect, the nanoparticles contain a core containing a PACE polymer optionally containing endgroup modifications, and a polymeric surfactant non-covalently conjugated to the surface of the nanoparticles. The nanoparticles contain a peptide or protein targeting moiety that is covalently conjugated to the PACE-PEG polymer or to the surfactant on the surface of the nanoparticles via a linkage that contains a succinimide or substituted sulfone moiety, respectively. The nanoparticles provide as a versatile platform for the delivery of nucleic acids, such as mRNA.
Absstract of: US2025241854A1
Provided herein are nanostructured lipid carrier compositions, and methods of making and using thereof. The compositions comprise a nanostructured lipid carrier (NLC), where the NLC comprises an oil core comprising a mixture of a liquid phase lipid and a solid phase lipid, a cationic lipid, a sorbitan ester, and a hydrophilic surfactant, and optionally a bioactive agent. The bioactive agent can be associated with the NLC. The compositions are capable of delivery of a biomolecule to a cell for the generation of an immune response, for example, for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the compositions and using the compositions for stimulating an immune response are also provided.
Absstract of: US2025241985A1
Disclosed herein are compositions comprising nanoliposomes useful for the treatment and prevention of stroke.
Absstract of: US2025241974A1
Materials and methods for modulating wound healing are described. Compositions including a phenolic acid extract of berries from the Vaccinium family are useful for promoting wound healing, and can be formulated in a cream, a serum or gel, or in a nanocellulose hydrogel.
Absstract of: AU2023394992A1
The present invention relates to a messenger RNA (mRNA)-based immunogenic composition that is capable of inducing a mammalian cell to produce an influenza virus-like particle (VLP). The immunogenic composition comprises one or more mRNAs encoding an influenza virus matrix 1 (M1) protein and one or more influenza virus hemagglutinin (HA) proteins and/or one or more influenza virus neuraminidase (NA) proteins.
Absstract of: AU2025205348A1
Abstract The present disclosure relates to a copolymer and a polymersome for targeted delivery of biomolecules to a living organism. Hie exemplary copolymer comprises an initiator block, a propagator block, and a linkage connecting the initiator block and the propagator block. The initiator block comprises a glycan head configured to provide a targeted delivery, and the propagator block comprises a functional moiety configured to provide desired properties for the polymersome. Abstract The present disclosure relates to a copolymer and a polymersome for targeted delivery of biomolecules to a living organism. Hie exemplary copolymer comprises an initiator block, a propagator block, and a linkage connecting the initiator block and the propagator block. The initiator block comprises a glycan head configured to provide a targeted delivery, and the propagator block comprises a functional moiety configured to provide desired properties for the polymersome.
Absstract of: US2025241999A1
Systems for enhanced delivery of functional, recombinant soluble uricase enzymes with long serum residence, low immunogenicity and potential for modification have been developed. Compositions and methods of use thereof of nanoparticles including recombinant soluble uricase enzymes are provided for oral administration to a subject. The nanoparticle compositions include recombinant soluble uricase enzymes that are not PEGylated, and have a serum residence time of hours, days or weeks following oral administration. A reduced level of side effects of the formulation provides an effective and safe drug delivery platform for treating Tumor Lysis syndrome and Lesch-Nyhan disease, as well as hyperuricemia and associated diseases or disorders.
Absstract of: US2025241864A1
Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle ranges from about 1 nm to 450 nm. Such a nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.
Absstract of: US2025243151A1
An ionizable lipid having a structure represented by the following formula (I):wherein Y is independently selected from a group consisting of —NH—, —O—, —S—, and a single bond; X is independently selected from —NR1R2 or a nitrogen-containing heteroaryl group; L1 and L2 are each independently selected from a group consisting of a C1-C10 alkylene group, a C2-C10 alkenylene group,R1 and R2 are each independently selected from a group consisting of H, a substituted or unsubstituted C1-C10 hydrocarbyl group, a substituted or unsubstituted C1-C10 heterohydrocarbyl group, a substituted or unsubstituted C6-C20 aryl group, and a substituted or unsubstituted C1-C20 heteroaryl group; R3 is a C5-C30 alkyl group; R4 is a C5-C30 alkyl group; n is an integer selected from 1 to 10; and m and p are each independently an integer selected from 1 to 20.
Absstract of: AU2024223881A1
The present invention relates to methods for the purification of lipid nanoparticles (LNPs) encapsulating a nucleic acid, comprising the steps of subjecting a solution containing said LNPs to a chromatographic medium with convective flow properties in the presence of at least one kosmotropic agent; and eluting LNPs from said chromatographic medium. The present invention further relates to respective uses of a chromatographic medium with convective flow properties for the purification of lipid nanoparticles (LNPs) encapsulating a nucleic acid.
Absstract of: AU2024206838A1
The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject that, optionally, have reduced reactogenicity and promotes a local innate immune response in the subject while promoting an adaptive immune response. Compositions described herein include nanoparticles, optionally including an inorganic particle, capable of admixing with nucleic acids encoding proteins, antibodies, or immunomodulators. Methods of using the compositions as a therapeutic vaccine for the treatment of an infection or cancer are also provided.
Nº publicación: AU2024209247A1 31/07/2025
Applicant:
UNIQURE BIOPHARMA B V
UNIQURE BIOPHARMA B.V
Absstract of: AU2024209247A1
41 P6105182WOThe invention relates to formulations comprising miRNA that have improved stability for the treatment of diseases including neurodegenerative diseases such as spinocerebellar ataxias type 3. 5
BOPI
Electronic site
